Tandem Diabetes Care (TNDM) Accumulated Depreciation & Amortization (2013 - 2025)

Tandem Diabetes Care has reported Accumulated Depreciation & Amortization for 13 years, with the latest figure at $17.7 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 6.38% year-over-year to $17.7 million; the trailing twelve-month figure through Dec 2025 stood at $17.7 million (up 6.38% YoY), and the FY2025 full-year result was $17.7 million, up 6.38% from the prior year.
• Accumulated Depreciation & Amortization for Q4 2025 stood at $17.7 million, up from $16.6 million in the prior quarter.
• The five-year high for Accumulated Depreciation & Amortization was $17.7 million in Q4 2025, with the low at $13.8 million in Q4 2021.
• Historically, Accumulated Depreciation & Amortization has averaged $15.6 million across 5 years, with a median of $15.7 million in 2023.
• Annual changes were most pronounced in 2021 — Accumulated Depreciation & Amortization soared 32.48% — and 2022, when it gained 3.5%.
• Tandem Diabetes Care's Accumulated Depreciation & Amortization stood at $13.8 million in 2021, then increased by 3.5% to $14.3 million in 2022, then grew by 9.67% to $15.7 million in 2023, then rose by 5.68% to $16.6 million in 2024, then gained by 6.38% to $17.7 million in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $17.7 million (Q4 2025), $16.6 million (Q4 2024), and $15.7 million (Q4 2023), per Business Quant data.